Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0000853 | uM | 7496.092 | 1.0378 | 1.0767 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000427 | uM | 7496.092 | 0.9797 | 0.9588 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00213 | uM | 7496.092 | 1.0175 | 1.0355 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0107 | uM | 7496.092 | 0.9952 | 0.9903 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0533 | uM | 7496.092 | 1.0025 | 1.0051 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.267 | uM | 7496.092 | 1.0057 | 1.0116 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 1.33 | uM | 7496.092 | 1.0141 | 1.0286 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 6.67 | uM | 7496.092 | 0.9657 | 0.9305 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 33.3 | uM | 7496.092 | 0.7844 | 0.5633 | 0.9861 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7498.091 | 1.0942 | 1.1637 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7498.091 | 1.0420 | 1.0732 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7498.091 | 1.0622 | 1.1083 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7498.091 | 1.0055 | 1.0095 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.107 | uM | 7498.091 | 1.0392 | 1.0683 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 0.533 | uM | 7498.091 | 1.0418 | 1.0729 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 2.67 | uM | 7498.091 | 1.0221 | 1.0386 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 13.3 | uM | 7498.091 | 0.9888 | 0.9804 | 1.1445 | |
| MDA-MB-157 | TNBC | Basal B | Erlotinib | EGFR | ErbB | 66.7 | uM | 7498.091 | 0.8376 | 0.7131 | 1.1445 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7499.09 | 0.9431 | 0.8770 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7499.09 | 0.9788 | 0.9541 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7499.09 | 0.9886 | 0.9754 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7499.09 | 0.9982 | 0.9960 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7499.09 | 0.9105 | 0.8069 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7499.09 | 0.8553 | 0.6886 | 0.9238 | |
| MDA-MB-175-VII | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7499.09 | 0.7882 | 0.5457 | 0.9238 |